Unveiling the role of PGCCs in tumor recurrence and therapeutic resistance: Hidden architects of cancer's comeback.

Polyploid Giant Cancer Cell (PGCCs) have emerged as pivotal players in cancer biology, contributing to tumor heterogeneity, recurrence, metastasis, and resistance to conventional therapies. Characterized by their enlarged size, aberrant nuclear morphology, and stem-like properties, PGCCs arise in response to environmental stressors such as chemotherapy, radiation, and hypoxia. These cells enter a dormant state, evade treatment, and later become reactivated to generate tumor-repopulating progeny through depolyploidization and asymmetric division (neosis). Daughter cells derived from PGCCs exhibit enhanced invasive capabilities, epithelial-to-mesenchymal transition (EMT), and metabolic adaptability, rendering PGCCs formidable obstacles in cancer management. Their unique biology involves complex molecular mechanisms including endoreplication, cell fusion, and autophagy, which facilitate survival and proliferation under stress conditions. Elucidating PGCC formation and behavior opens new avenues for targeted therapeutic strategies, encompassing immunomodulation, metabolic interference, and differentiation-based approaches. This paradigm shift in cancer research underscores the urgency for innovative diagnostic tools and personalized treatment modalities to effectively counter PGCC-driven malignancies.